Experienced medical industry executive to help company implement strategic plan in its next phase of clinical studies and market development
Rocky Hill, Connecticut – July 20, 2021 – Lumeda Inc., a medical technology company advancing Photodynamic Therapy (PDT) as an intraoperative adjuvant treatment for patients during lung cancer surgery, today announced the appointment of Jason Pesterfield to its board of directors. A seasoned healthcare industry executive with significant experience in surgical navigation systems and thoracic surgery devices, Mr. Pesterfield will contribute to the company’s implementation of its strategic plan and engagement with physicians to move toward commercialization of Lumeda’s photodynamic therapy (PDT) product as an adjuvant treatment applied intraoperatively in lung cancer tumor resection and palliative pleural procedures.
“We are excited to have Jason join our board of directors to bring his deep experience in lung cancer surgery and global connections to thoracic surgeons and interventional pulmonologists” said Lumeda CEO, Sandy Zinke. “Jason has significant expertise in developing innovative commercialization strategies to launch new medical technologies in the lung cancer space. He brings a network of industry contacts that will help Lumeda develop key relationships with medical thought leaders and commercial partners to accelerate the introduction and adoption of Lumeda’s novel technology.”
Mr. Pesterfield has over 25 years of global medical device experience, most recently as CEO of Veran Medical, acquired by Olympus Medical in December, 2020. Prior to that, he led Stryker Corporation’s Surgical Navigation Division where he was responsible for executing over 50 product launches, driving significant global growth and escalating the company market share and position under his tenure.
“I am excited to be joining the talented Lumeda team to help them introduce this important adjuvant therapy for treating lung cancer,” said Pesterfield. “The Lumeda PDT light dosimetry system represents a viable treatment option without the severe side effects of other adjuvant therapies for improved patient outcomes and quality of life”.
Lumeda is advancing PDT to treat NSCLC and other thoracic malignancies. The company applies advanced photonics and proprietary software to automate and digitize PDT light delivery to improve PDT efficacy, ease of use and treatment planning. The multidisciplinary Lumeda team has decades of experience in the photonics industry, with expertise in systems engineering and commercialization of new technology. Lumeda is committed to pioneering the advancement and utility of PDT for improved patient outcomes. For more information, please visit lumedainc.com.